Transforming Metabolic Dysfunction-Associated Steatohepatitis Management: Pharmacist Considerations for the Evolving Treatment Landscape

This activity was originally presented live at Asembia's AXS25 Summit in Las Vegas, Nevada on April 28, 2025.

Program Description
Metabolic dysfunction-associated steatohepatitis (MASH), a progressive form of fatty liver disease linked to metabolic syndrome, is becoming an increasingly significant public health challenge. As a leading cause of liver-related morbidity, MASH contributes to the rising demand for liver transplantation and ongoing need for therapies that address both liver inflammation and the metabolic factors contributing to disease progression. Current standard of care involves lifestyle modifications, which often yield limited results. However, advances in treatment options have emerged, with an FDA-approved, orally administered partial activator of a thyroid hormone receptor therapy and several GLP-1 receptor agonists under investigation for MASH. This educational program will provide tools for specialty pharmacists to identify the clinical presentation of MASH, support timely interventions, and improve care delivery to alleviate the growing burden of MASH. 

Target Audience: Managed care and specialty pharmacists

Type of Activity: Application
Release date: May 12, 2025
Expiration date: May 12, 2026
Learner level: Foundational
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Apply knowledge of updated metabolic dysfunction-associated steatohepatitis (MASH) terminology, epidemiology, and risk factors to identify patients at risk and guide management decisions
• Interpret current clinical guidelines for MASH to align patient care with recommended management strategies
• Investigate the efficacy and safety of current and emerging therapies for MASH to optimize treatment plans for individual patients
• Determine strategies for specialty and managed care pharmacists to enhance patient care through education, preventive care, and the integration of emerging therapies into clinical practice

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-141-H01-P. The activity is available for CE credit through May 12, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Naim Alkhouri, MD, FAASLD, DABOM, has the following relevant financial relationships with commercial interests to disclose:

Grant/Research Support: 89bio, Akero Therapeutics, Arbutus Biopharma, AstraZeneca, BioAge, Boehringer Ingelheim, Bristol Myers Squibb, Corcept Therapeutics, CymaBay Therapeutics, DSM, Galectin Therapeutics, Genentech, Genfit, Gilead Sciences, Healio, Hepagene Therapeutics, Intercept Pharmaceuticals, Inventiva Pharma, Ionis Pharmaceuticals, Ipsen, Lilly, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Noom, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, PharmaIN, Poxel, Viking Therapeutics, and Zydus. Consultant: 89bio, Akero Therapeutics, Boehringer Ingelheim, Echosens, Fibronostics, Gilead Sciences, Intercept Pharmaceuticals, Ipsen, Madrigal Pharmaceuticals, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, Regeneron. Speakers Bureau: AbbVie, AstraZeneca, Echosens, Gilead Sciences, Intercept Pharmaceuticals, Ipsen, Madrigal Pharmaceuticals, and Novo Nordisk

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Dovena Lazaridis, PharmD, BCACP

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta, and Rebecca Green.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms